Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

Summary

Phase II, multicenter, national, uncontrolled, multicenter, uncontrolled, phase II clinical trial for the evaluation of cabozantinib treatment prior to cytoreductive nephrectomy in patients with advanced or metastatic renal cell cancer candidates for primary tumor cytoreductive nephrectomy (NC).

Timeline

Start

2018-11-01

Primary completion

2022-08-09

Completion

2022-08-09

Outcome

Outcome not reported

Stopped: “The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive final result analysis was conducted, as presented herein.”

Drugs

Indications